Next-generation genetically modified foods need better regulation
By Dana Perls,
STAT
| 02. 02. 2017
The apple that never browns wants to change your mind about genetically modified foods.”
That headline in the Washington Post is just one of many shining the spotlight on the next generation of genetically modified organisms (what many are calling GMO 2.0) heading to our supermarkets and restaurants.
Gene-silenced Arctic apples that do not turn brown when exposed to air, even when rotten, will be sold in stores in the Midwest this week. Other products on the way include canola oil extracted from rapeseed that has been modified by gene editing to withstand more pesticides, but which is being marketed as a non-GMO food by its maker; salmon genetically engineered with eel genes to grow faster; and synthetic vanillin excreted from genetically modified yeast, yet marketed as “natural.”
Researchers are tinkering with nature’s DNA in new and potentially problematic ways and without clear regulatory guidance. They can alter a species by editing or deleting genes, turning genes on or off, or even creating completely new DNA sequences on a computer. Some of these new foods will be marketed as “non-GMO” or...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...